Altimmune vs Inmune Bio
ALT and INMB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALT and INMB compare
Altimmune is the larger company, worth 11 times as much as Inmune Bio ($320M against $29.1M).
Inmune Bio scores higher on the StockData Score (6 against 4 for Altimmune), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALT | INMB |
|---|---|---|
| Size and price | ||
| Market cap | $320M | $29.1M |
| Share price | $1.65 | $1.05 |
| Change, 1 year | −61.1% | −30.9% |
| Change, 5 years | −84.4% | −92.1% |
| Beta (5Y) | 1.07 | 1.32 |
| Employees | 13 | 6 |
| StockData Score | ||
| Total score | 4 | 6 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.7× (better) | 1.6× |
| FCF yield | −32.0% | – |
| Growth | ||
| Revenue growth, 5Y average | −65.3% | 35.4% (better) |
| Profitability | ||
| Return on equity | −33.2% (better) | −76.7% |
| Return on invested capital | −89.7% | – |
| Financial health | ||
| Debt / equity | 0.08 (better) | 0.00 |
| Interest coverage | −27.6× | – |
| Current ratio | 23.93 (better) | 6.41 |
| Altman Z-score | 1.51 (better) | −11.10 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | −22.1% | – |
| Shareholder yield | −22.1% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 77.9% | 15.7% |
| Held by insiders | 0.51% | 16.7% |
| Insider net buying, 12 months | $370K | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 21.8% | 11.5% |
Go deeper
- ALT stock overview
- ALT income statement
- ALT valuation and score
- INMB stock overview
- INMB income statement
- INMB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.